Twist Bioscience (TWST) Stock
Synthetic DNA manufacturer for biotech and diagnostics. Here's the price, business snapshot, and what's worth knowing about Twist Bioscience in August 2026.
Twist Bioscience Corporation is a synthetic biology company that manufactures DNA using a proprietary silicon-based platform. Its products serve markets including genetic research, diagnostics, industrial biotechnology and therapeutic development, supplying synthetic DNA, oligos and related services to biotech and pharmaceutical customers. Investors should know Twist is positioned in an emerging, high-growth segment of life sciences where demand for custom DNA and sequencing‑ready products can increase as genomics, cell and gene therapies, and diagnostics expand. The company has pursued partnerships and commercial contracts to broaden revenue channels, but still faces typical biotech execution risks: scaling manufacturing, achieving sustained profitability and managing R&D and capital needs. As a small-cap equity (market cap roughly $2.0bn), TWST can be more volatile than large-cap peers. This summary is for educational purposes only and not personal financial advice; investors should check the company’s latest results, cash runway and competitive landscape before deciding suitability for their portfolio.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts are highly optimistic about Twist Bioscience's stock, predicting significant value growth ahead.
Financial Health
Twist Bioscience is performing well with solid revenue and cash flow, showing strong profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Synthetic biology exposure
Twist offers exposure to the expanding market for engineered DNA used in therapeutics and diagnostics, though growth can be uneven and competition is strong.
Partnerships and customers
Collaborations with pharma and diagnostics firms can diversify revenue and validate technology, but customer concentration and contract timing remain factors to monitor.
Execution and cash
Scaling manufacturing and moving toward sustained profitability are key milestones; capital requirements and cash runway deserve careful review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
